This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Dong-Ya Zhu
Laboratory of Cerebrovascular Disease, Nanjing Medical University
Corresponding Author
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Disrupting the nNOS–PSD95 interaction could selectively inhibit the NMDARs-nNOS signal pathway, without blocking NMDARs function and catalytic activity of nNOS, thereby sparing unwanted effects on many other important physiological processes mediated by the NMDARs and nNOS. In this protocol, 4-(3,5-Dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid, a nNOS-PSD95 interrupter, we named it ZL006, was prepared by the condensation of 3,5-dichlorosalicylaldehyde and 4-aminosalicylic acid, and the reduction of the condensation production with sodium borohydride. We synthesized the derivatives of ZL006 also.
Keywords
cerebral ischemic damage, ZL006, N-methyl-D-aspartate receptors, nNOS-PSD95 interaction
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
No
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 06 Jan, 2011
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95
by Li Zhou, Fei Li, Hai-Bing Xu, +7
Nature Medicine (29 December, 2010)
Method Article
Dong-Ya Zhu
Laboratory of Cerebrovascular Disease, Nanjing Medical University
Corresponding Author
Version History
CURRENT STATUS: Posted
Version 1
Posted 06 Jan, 2011
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Disrupting the nNOS–PSD95 interaction could selectively inhibit the NMDARs-nNOS signal pathway, without blocking NMDARs function and catalytic activity of nNOS, thereby sparing unwanted effects on many other important physiological processes mediated by the NMDARs and nNOS. In this protocol, 4-(3,5-Dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid, a nNOS-PSD95 interrupter, we named it ZL006, was prepared by the condensation of 3,5-dichlorosalicylaldehyde and 4-aminosalicylic acid, and the reduction of the condensation production with sodium borohydride. We synthesized the derivatives of ZL006 also.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Associated Publications
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95
by Li Zhou, Fei Li, Hai-Bing Xu, +7
Nature Medicine (29 December, 2010)